

## **Disclosure of Transfers of value to HCPs/HCOs**

### **2021 Self-Certification**

Healthcare professionals (HCPs) and healthcare organisations (HCOs) with whom SC ANGELINI PHARMACEUTICALS ROMANIA SRL (“Angelini Pharma”) works, provide the Pharmaceutical Industry with valuable, independent and expert knowledge derived from their clinical and management experience. As owners of scientific knowledge and experts in medicinal products, pharmaceutical companies can be a unique resource to the healthcare systems and providers, which will ultimately benefit the patients.

Throughout the medicines life cycle, pharmaceutical companies work with scientists and HCPs. These collaborations are essential in addressing patient needs. Industry and HCPs collaborate in a range of activities from clinical research to sharing best clinical practice and exchanging information on how new medicines fit into the patient pathway.

Romanian Association of International Medicine Manufacturers (ARPIM) - as member of EFPIA - has adopted codes and guidelines to ensure that the interactions of their member companies with HCPs and HCOs meet the high standards of integrity and transparency. Building greater transparency to the relationships between pharmaceutical companies and HCPs/HCOs aims to building understanding of the collaboration and recognition of its value to patient care.

EFPIA and its members are fully committed to implement and apply the highest ethical standards. Despite the exceptional circumstances related to COVID-19, Angelini Pharma made its best efforts to disclose the relevant information for 2020, also following the “EFPIA ethical guidance in light of COVID-19”.

Angelini Pharma hereby confirms that its disclosure of transfers of value (ToVs) to HCPs and HCOs made in 2020 has been reported in application of the ARPIM Code of Ethics following key principles:

#### **Disclosure quality**

Angelini Pharma certifies that:

- its disclosures are made in Romania;
- its disclosure includes direct and indirect ToVs, as defined in the codes and associated guidance issued by ARPIM;
- cross-border ToVs made by the other Angelini Pharma Countries are disclosed as communicated, in accordance with ARPIM;
- cross-border ToVs to Recipients abroad are communicated to the other Angelini Pharma Countries, in accordance with ARPIM;
- its Methodological Note describes the process it has followed in order to compile the data hereby disclosed.

**Methodology used for the collection and organisation of ToVs is in line with the ARPIM Code of Ethics requirements and applicable codes.**



Angelini Pharma certifies that:

- Data collection complies with the requirements of the ARPIM Code of Ethics;
- Actions are taken to ensure individual disclosure for HCPs and HCOs' transfers of values (each as defined in the ARPIM Code of Ethics).

**Aggregate disclosures are limited to Research and Development ToVs and such ToVs that cannot be disclosed on an individual basis for legal reasons.**

Angelini Pharma certifies that aggregate disclosure is limited to the following topics:

- Research and Development Transfers of Value (as defined in the ARPIM Code of Ethics);
- Costs related to Events that are clearly related to Research and Development activities can be included in the aggregate amount under the "Research and Development Transfers of Value" category.

#### **Ensuring compliance with Data Privacy Obligations**

Angelini Pharma certifies that the collection, processing and disclosure of transfers of value have been made in accordance with Data Privacy obligations.

**Date:** 08<sup>th</sup> June, 2021  
**Name of signatory:** Gabriele Jannis  
**Position in the Company:** General Manager  
**Signature:** 